TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer.
Saved in:
| Title: | TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer. |
|---|---|
| Authors: | Schmid P; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London EC1M 6AU, UK., Oliveira M; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., O'Shaughnessy J; Texas Oncology, Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA., Cristofanilli M; Department of Medicine, Weill Cornell Medicine, New York, NY, USA., Graff SL; Brown University Health Cancer Institute, Legorreta Cancer Center, Brown University, Providence, RI, USA., Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea., Loi S; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia., Saji S; Department of Medical Oncology, Fukushima Medical University, Fukushima, Japan., Wang S; Department of Medical Oncology, Cancer Center of Sun Yat-sen University, Guangzhou, China., Cescon DW; Department of Medical Oncology, Princess Margaret Cancer Centre/UHN, Toronto, ON, Canada., Hovey T; Biostatistics, Phastar UK (under contract to AstraZeneca), London, UK., Nawrot A; Oncology R&D, AstraZeneca, Warsaw, Poland., Tse K; Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Vukovic P; Oncology R&D, AstraZeneca, Cambridge, UK., Curigliano G; Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy.; Department of Oncology and Haemato-Oncology, University of Milano, Milan, Italy. |
| Source: | Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2025 Apr 17; Vol. 17, pp. 17588359251327992. Date of Electronic Publication: 2025 Apr 17 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1758-8340 |
|---|---|
| DOI: | 10.1177/17588359251327992 |
